NASDAQ:CODX - Co-Diagnostics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Co-Diagnostics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.98 0.00 (0.00 %) (As of 12/13/2019 06:25 AM ET) Add Compare Today's Range$0.98Now: $0.98▼$1.0050-Day Range$0.87MA: $0.95▼$1.0452-Week Range$0.69Now: $0.98▼$3.77Volume33,214 shsAverage Volume97,511 shsMarket Capitalization$16.78 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. Co-Diagnostics, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CODX Previous Symbol CUSIPN/A CIK1692415 Webhttp://www.codiagnostics.com/ Phone801-438-1036Debt Debt-to-Equity RatioN/A Current Ratio10.01 Quick Ratio9.96Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$40,000.00 Price / Sales419.44 Cash FlowN/A Price / Cash FlowN/A Book Value($0.08) per share Price / Book-12.25Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-6,270,000.00 Net Margins-5,486.08% Return on Equity-202.74% Return on Assets-152.56%Miscellaneous Employees22 Outstanding Shares17,120,000Market Cap$16.78 million Next Earnings Date2/12/2020 (Estimated) OptionableNot Optionable Receive CODX News and Ratings via Email Sign-up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CODX Rates by TradingView Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions What is Co-Diagnostics' stock symbol? Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX." How were Co-Diagnostics' earnings last quarter? Co-Diagnostics Inc (NASDAQ:CODX) announced its quarterly earnings data on Wednesday, November, 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.02. The company earned $0.04 million during the quarter, compared to analysts' expectations of $0.10 million. Co-Diagnostics had a negative net margin of 5,486.08% and a negative return on equity of 202.74%. View Co-Diagnostics' Earnings History. When is Co-Diagnostics' next earnings date? Co-Diagnostics is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Co-Diagnostics. What price target have analysts set for CODX? 2 brokerages have issued 12-month price targets for Co-Diagnostics' stock. Their forecasts range from $2.00 to $2.00. On average, they expect Co-Diagnostics' stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 104.1% from the stock's current price. View Analyst Price Targets for Co-Diagnostics. What is the consensus analysts' recommendation for Co-Diagnostics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Co-Diagnostics. Has Co-Diagnostics been receiving favorable news coverage? Media headlines about CODX stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Co-Diagnostics earned a media sentiment score of 1.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Co-Diagnostics. Are investors shorting Co-Diagnostics? Co-Diagnostics saw a increase in short interest in November. As of November 29th, there was short interest totalling 549,200 shares, an increase of 18.4% from the November 14th total of 464,000 shares. Based on an average trading volume of 76,700 shares, the days-to-cover ratio is presently 7.2 days. Approximately 5.1% of the company's stock are short sold. View Co-Diagnostics' Current Options Chain. Who are some of Co-Diagnostics' key competitors? Some companies that are related to Co-Diagnostics include Nephros (NEPH), Apollo Endosurgery (APEN), Sensus Healthcare (SRTS), Pro-Dex (PDEX), T2 Biosystems (TTOO), Nephros (NEPHD), Arch Therapeutics (ARTH), BeyondAirInc . (XAIR), SANUWAVE Health (SNWV), AIT Therapeutics (AITB), Endologix (ELGX), Invo Bioscience (IVOB), PAVmed (PAVM), Neovasc (NVCN) and Biostage (BSTG). What other stocks do shareholders of Co-Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Bausch Health Companies (BHC), Advanced Micro Devices (AMD), Alibaba Group (BABA), Teva Pharmaceutical Industries (TEVA), Corbus Pharmaceuticals (CRBP), CytomX Therapeutics (CTMX), Zynerba Pharmaceuticals (ZYNE), AT&T (T), Array Biopharma (ARRY) and bluebird bio (BLUE). Who are Co-Diagnostics' key executives? Co-Diagnostics' management team includes the folowing people: Mr. Dwight H. Egan, Chairman, CEO & Pres (Age 66)Dr. Brent C. Satterfield, Co-Founder, Chief Science Officer & Director (Age 42)Mr. Reed L. Benson, CFO, Gen. Counsel & Sec. (Age 71)Dr. Mayuranki Almaula, Sr. VP of Overseas Operations & Strategic AlliancesMr. Cameron Gundry, Head of Commercialization LATAM/EUR When did Co-Diagnostics IPO? (CODX) raised $9 million in an IPO on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO. Who are Co-Diagnostics' major shareholders? Co-Diagnostics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Barclays PLC (0.43%). View Institutional Ownership Trends for Co-Diagnostics. Which major investors are buying Co-Diagnostics stock? CODX stock was acquired by a variety of institutional investors in the last quarter, including Barclays PLC. View Insider Buying and Selling for Co-Diagnostics. How do I buy shares of Co-Diagnostics? Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Co-Diagnostics' stock price today? One share of CODX stock can currently be purchased for approximately $0.98. How big of a company is Co-Diagnostics? Co-Diagnostics has a market capitalization of $16.78 million and generates $40,000.00 in revenue each year. Co-Diagnostics employs 22 workers across the globe.View Additional Information About Co-Diagnostics. What is Co-Diagnostics' official website? The official website for Co-Diagnostics is http://www.codiagnostics.com/. How can I contact Co-Diagnostics? Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE - D, SALT LAKE CITY UT, 84109. The company can be reached via phone at 801-438-1036 or via email at [email protected] MarketBeat Community Rating for Co-Diagnostics (NASDAQ CODX)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 202 (Vote Outperform)Underperform Votes: 224 (Vote Underperform)Total Votes: 426MarketBeat's community ratings are surveys of what our community members think about Co-Diagnostics and other stocks. Vote "Outperform" if you believe CODX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CODX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/13/2019 by MarketBeat.com StaffFeatured Article: How to Invest in Stocks with Increasing Dividends